Thus, while there are more than 200 biologic drugs approved by the FDA, only 23 biosimilars have been FDA approved.1. Insight provided by Bryan Klazinga, VP of Pharmacy Benefits. Emerging oncology treatments, particularly immunotherapy, are a major medical pharmacy trend driver. Health care data, analytics and technology, https://www.fda.gov/drugs/biosimilars/biosimilar-product-information, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606858/, https://www.reuters.com/article/us-abbvie-amgen-humira/abbvie-amgen-settlement-sets-humira-u-s-biosimilar-launch-for-2023-idUSKCN1C32G5, https://www.biopharmadive.com/news/amgen-allergan-launch-first-us-biosimilars-of-roches-herceptin-and-avasti/559130/, https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-orphan-drug-report-2019, https://icer-review.org/wp-content/uploads/2018/02/ICER_Amyloidosis_Final_Evidence_Report_100418.pdf, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485616/, https://icer-review.org/wpcontent/uploads/2017/06/MWCEPAC_VORETIGENE_FINAL_EVIDENCE_REPORT_02142018.pdf, https://www.ncbi.nlm.nih.gov/books/NBK538378/, Language Assistance / Non-Discrimination Notice, Asistencia de Idiomas / Aviso de no Discriminación. Pharmacy & Therapeutics. For the large drug store retail chains, the share of retail revenues resulting from front-of-store sales dropped about 4% to 6% between 2013 and 2016 (e.g., from 52% to 46% at CVS and from 37% to 33% at Walgreens). Currently, 65% of total drug spend is handled via the pharmacy benefit and 35% is handled via the medical benefit. Specialty pharmacy has been a top trend for the past several years as utilization and drug spend have dramatically increased across healthcare. This lack of competition between biosimilars will impact the overall comparative economics of the biosimilar versus innovator brand. New treatments aimed at rare diseases (also known as ‘orphan drugs’) are also emerging at a pace much faster than most other drugs. Health plan sponsors are rightly concerned about the possibility that their medical costs could skyrocket if a few of their members started treatment. In contrast, biologic drugs are much larger molecules developed via much more complex modifications of live microorganisms in the human body, and thus exact chemical synthesis and replication is not possible. “Orphan Drug Report 2019.” Accessed at: https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-orphan-drug-report-2019 Trends in Specialty Pharmacy Management | Population Health Learning Network These changes alter gene function in order to address the genetic causes of a disease. “Voretigene Neparvovec for Biallelic RPE65-Mediated Retinal Disease: Effectiveness and Value.” Accessed at: https://icer-review.org/wpcontent/uploads/2017/06/MWCEPAC_VORETIGENE_FINAL_EVIDENCE_REPORT_02142018.pdf Moreover, fast-track development of new pharmaceutical industries, major merges and acquisitions among pharmacies, and improvement in pharmacy benefit management (PBM) and healthcare plans, are anticipated to bring about consolidation in the specialty pharmaceuticals market. According to Express Scripts 2007 Drug Trend Report in 2007 there was a 14% increase in specialty drugs. Drugs covered by the medical benefit are administered by a health care provider (often via IV infusion) to the patient. BioPharmaDive.  “Amgen, Allergan launch first US biosimilars of Roche's Herceptin and Avastin.” Accessed at: https://www.biopharmadive.com/news/amgen-allergan-launch-first-us-biosimilars-of-roches-herceptin-and-avasti/559130/ 8. 7. This new version of a biologic formula is classified as a biosimilar. Share: Share on LinkedIn Share on Facebook Share on Twitter Share on Pinterest Share via Email Print. Examines SPPs' manufacturer "Partner of Choice," manufacturer collaboration initiatives with SPPs, best-in-class account manager nominations, and and benchmark ratings of manufacturers in account support and willingness to contract. In addition to the type of specialty medicines now in the marketplace, it is important to understand how and where specialty medicines are administered and how they are paid for. and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. report captures directional trends in the LHS specialty pharmacy market. In 2018, two new drugs were approved to treat polyneuropathy due to Hereditary ATTR (hATTR) amyloidosis, a rare disease estimated to impact 10,000 people worldwide.6, The drugs, Onpattro® and Tegsedi™, employ variants of RNA therapy to transfer bits of genetic code to prevent production of the mutated TTR protein, which halts the disease. Click here if you can’t see the video below. This article is directed solely to its intended audience about important developments affecting the pharmacy benefits business. 1. Looking ahead, drugs for rare diseases now constitute a growing part of the pipeline and are expected to account for 22% of all prescriptions drug sales by 2024. 10,11 Specialty products have given … Keytruda had an impactful increase in utilization, with PMPM trend … Luxturna uses specially engineered viruses to essentially “smuggle” the drug past the body’s immune defenses and permanently alter the part of the genetic code responsible for the disease. While they are relatively recent, some have been on the market long enough to have outlived the usual period of market exclusivity. These therapy programs seamlessly merge member education, digital tools, and clinical expertise dedicated specifically to a given disease. Gene therapies change either DNA or RNA molecules – essentially the code readers for our genes. 5. The number of specialty drugs entering the market will continue to grow in 2019, along with the price of each new drug. At launch the price of Luxturna was $425,000 per eye.8, Additional DNA-based gene therapies are in development for diseases including hemophilia and sickle cell anemia.9. San Francisco—Building on the knowledge base from earlier editions, the eighth annual edition of the EMD Serono Specialty Digest™ has been released. A few companies … Specialty drug spend is growing. Specialty pharmacy, So far, only 16 biosimilars have received FDA approval, of those, only six have reached the … Pharmacy care services, Tag: “Gene Therapy: An Overview of Approved and Pipeline Technologies.” Accessed at: https://www.ncbi.nlm.nih.gov/books/NBK538378/. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. “With biosimilars, we are not seeing that.”, The lack of biosimilars is linked to these price discrepancies by a thicket of legal challenges and patents that biosimilar makers face. These new therapies have resulted in eradicating diseases, or extending the lives or quality of those lives of millions of individuals. Many important medications on the market today are classified as biologic drugs. “Our approach is to have a therapy-specific team within our pharmacies, and to make sure that they have dedicated support. Gross cost does not exclude member cost share, and it is net of rebates adjusted for other pharmaceutical … Patients with hemophilia have long relied on concentrated blood clotting factors to help control the bleeding episodes associated with the disease. 2 In 2018, the top seven dispensing pharmacies—CVS Health, Walgreens Boots Alliance, Cigna / … Specialty Pharmacy Trends and Strategies: 2013 | Atlantic Information Services, Inc., Erin Trompeter, Susan Namovicz-Peat | ISBN: 9781936230518 | Kostenloser Versand für alle Bücher mit Versand und Verkauf duch Amazon. As the accompanying video attests, these advances can have a profound impact on the lives of hemophilia patients and their loved ones. In order for a specialty pharmacy to be successful, the pharmaceutical industry must bring more innovative products to market. By 2008 there were more than 200 specialty pharmaceuticals on the market. Prescribers and patients will expect a seamless experience that begins with your health system pharmacy. Top specialty drug pharmacies in the U.S. by revenue 2019; Top revenue growth rates of private specialty pharmacies U.S. 2015-2018; Revenue of top growing private specialty pharmacies in U.S. 2018 80% of new drug approvals are considered specialty (Source: Walgreens, CBI, January 2016). Your system will expect you to procure them and have health plans reimburse you for them. But for biologics, the situation is more complicated, and more challenging. Specialty drugs represent one of the fastest growing segments in the healthcare industry, with projections estimating that specialty drugs will represent nearly 40% of total drug spend by 2020, relative to 28% in 2016. While not appropriate for all specialty drugs, shifting certain medicines from the medical benefit to the pharmacy benefit unlocks an array of cost management strategies and can result in significant PMPM savings. Biologics are complex medications made from living cells. According to UNAIDS, 35.3 million people are living with HIV/AIDS worldwide; more than 1.1 million people are living with HIV in the United States. You need key relationships in place with … In general, drugs covered under the pharmacy benefit are self-administered; that is, the patient takes them on their own. Surprise! David Lassen, chief clinical officer at Prime Therapeutics, discusses important developments in specialty pharmacy . provider and stakeholder should have a specialty pharmacy strategy.1 In 2018, specialty drugs accounted for more than one-third of the pharmacy industry’s total prescription-dispensing revenue. Specialty Pharmacy Trends Report: HIV/AIDS. Specialty products and services were considered the most profitable among all the pharmacy trends for this year, and 2020 will see a bigger market for these medications as they become part of the top pharmacy trends for 2020. Press release - Orion Market Reports - Specialty Pharmaceuticals Market Trends, Share, Industry Size, Growth, Analysis and Forecast - 2019 to 2025 - published on openPR.com In addition to the manufacturing challenges of making a product as identical as possible to the reference biologic drug, biosimilars also face a different approval process. So, the patient experience drives everything.”, Tag: This event has more diversity than any other industry event. The healthcare system is shifting in its pharmaceutical delivery model, with more targeted, high dollar therapies procured through specialty pharmacy. Over time, the result will be an expanding footprint for specialty pharmacies and a much greater relevance in the … Another recently emerging driver of change in specialty pharmacy is the availability of gene therapies. Brand-Name Drug Prices Fell (Again) in 2020, The Big Three PBMs Ramp Up Specialty Drug Exclusions for 2021, How GoodRx Profits from Our Broken Pharmacy Pricing System, Specialty Pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 Will Accelerate It (rerun), Preferred Pharmacy Networks Dominate in 2021 Medicare Part D Plans: The Scoop on Cigna, CVS Health, Humana, WellCare, and More. An overview of the drivers of change in specialty pharmacy. “Once the prescription is dispensed, and the patient receives it, we need to make sure that they are getting the benefit out of it,” Zeglinski says. With ordinary “small molecule” drugs, this is when we expect to see the entrance of generic versions – often at a far lower cost. Key examples include two biosimilars recently launched for the popular cancer drugs, Avastin® and Herceptin®.4. 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. 2 Emerging Trends in the Specialty Drug Industry Brought to you By: S pecialty drugs have revolutionized medicine in the last two decades, helping improve survival and quality of life for untold numbers of patients with chronic diseases. Asembia’s Specialty Pharmacy Summit remains the undisputed champion for conducting business in the specialty marketplace. Total cost management, Genome Medicine. Webinar, Canadian Agency for Drugs and Technologies in Health. On average the costs for orphan drug products is ~$150,000 per patient per year.5. Healthcare executives should continue to monitor specialty medical pharmacy claim information and trends, according to Eric McKinley, PharmD, director, specialty clinical solutions at Magellan Rx Management. 9 In response to this trend, many of the large retail chains are attempting to move deeper into pharmacy benefit management, specialty pharmacy, or retail healthcare. Where a given drug must remain under the medical benefit, OptumRx has created a specialty guidance program to help manage these costs. This shift… Institute for Clinical and Economic Review. Below are specialty pharmacy’s top trends: New Specialty Products and Continued Growth Specialty pharmacy became a reality as the result of the emergence of new drug approvals for disease states that lacked adequate therapy or no therapy at all. Although similarities exist, biosimilars face several unique challenges that have combined to limit their usage in the U.S. Generics drugs are exact copies of the small molecule innovator brand drugs that have lost patent exclusivity. Yet, within that medical benefit drug spending, specialty drugs account for a majority of that total. As in previous years, the largest manufacturers, wholesalers, and pharmacies sent dozens of representatives. The 2019 Summit attracted an incredible range of job functions and organizations. When the patent on a biologic expires, it opens the door for pharmaceutical companies to develop their own version of these medications. Roughly half of specialty drugs are administered in the hospital, and half at a physician’s office, with a small percentage dispensed at specialty pharmacies, infusion centers or in the home. In addition to orphan drugs, which are aimed at diseases or conditions affecting fewer than 200,000 people in U.S., there are now “ultra-orphan” drugs, which are intended for an even smaller numbers of people. We know that when multiple generic manufacturers compete in the non-biologic space to replicate a single traditional drug, those generics can cost up to 85% less than the brand-name drug. You can watch the full video below. 5 trends impacting specialty pharmacy. Die Erhebung wird in der Kategorie Rx seit dem Jahr 2000 in Deutschland jährlich bei niedergelassenen Ärzten und seit 2018 in den Kategorien OTC (Apotheker und Patienten), Orphan Drugs (Klinikärzte) und Startups sowie seit 2019 in der Kategorie Specialty Care (Klinikärzte) zusätzlich durchgeführt. We have created a suite of therapy-specific programs designed to offer specialty patients dedicated support for specific disease states. Recently, a new drug which works differently than other hemophilia medications came to market. Pembroke Consulting, Inc., and. 3. Accordingly, we have identified five primary drivers of change in the specialty marketplace: Complex biologically engineered drugs (“biologics”) are among the most expensive drugs on the market. This rapid growth, especially within the context of a constantly evolving macro healthcare environment, has created a number of new industry dynamics that have radiated throughout the pharmaceutical … Der Pharma Trend ist die Erhebung zu Innovation und Nachhaltigkeit von Pharma-Unternehmen. This means that, not only are there rarely biosimilars to compete with the branded biologics, there are almost never enough biosimilars to compete with each other in the same category. Specialty trend was... More. For example, Optum Specialty Pharmacy's hemophilia and bleeding disorders-specific program provides new hemophilia patients with a dedicated nurse navigator and concierge teams in order to deliver a world-class member experience. Institute for Clinical and Economic Review. Specialty and high-cost medications continue to dominate the news. Switching the site of care to infusion centers, clinics or the home can save thousands per impacted member annually. Reuters. It is not intended to promote the use of any drug mentioned in the article and neither the author nor OptumRx has accepted any form of compensation for the preparation or distribution of this article. Specialty Pharmacy Keeps Disrupting Buy-and-Bill—a... Preorder now: The 2020-21 Economic Report on Pharm... Three Ways to Boost Patient Access to Orphan Drugs... My Wall Street Journal Op-Ed about the 340B Program. Complex conditions, Specialty Pharmacy; Roadblocks and Remedies: Succeeding in Health System Special... Over the past decade, health systems have invested in specialty pharmacies at a growing rate. “Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.” Accessed at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606858/ By leveraging OptumRx prior authorization tools, guidelines, data and analytics, and clinical expertise clients can realize the full value of these costly medications. These products are easily produced via chemical synthesis in the lab. Specialty pharmacy has been a top trend for the past several years as utilization and drug spend have dramatically increased across healthcare. Specialty medication is expected to increase to 50% of drug costs by 2020. In 2019, drug trend for CVS Caremark pharmacy benefit clients was a historically low, industry-leading 1.4 percent, with 41% of clients seeing negative trend. While these treatments represent new and potentially life-altering options for the people who use them, they can be extremely expensive. Instead of generics, biologic replacements are called ‘biosimilar’ drugs. Social Share. Biosimilar Product Information. Specialty Pharmacy Providers: Manufacturer Engagement and Contracting Trends June 2020. The State of Specialty Pharmacy 2020: Market Data ... Why Do CVS And Express Scripts Rely on Secretive P... Copay Maximizers Are Displacing Accumulators—But C... Walgreens and CVS Top the 28,000 Pharmacies Profit... PBMs and Drug Spending in 2019: CVS Health and Exp... ‘Smart pill’ company etectRx and Pear Therapeutics form CNS partnership, NCPA files lawsuit against HHS to eliminate spiraling pharmacy DIR fees, STAT+: Maryland Senate overrides governor’s veto of prescription drug affordability board, PCMA Welcomes Additions to Regulatory Affairs, Research Teams, Gilead partner Arcus earns analysts' plaudits for early pancreatic cancer data that 'exceeded expectations', Research shows gene therapies can offer cost savings potential of up to $1.8M over five years for patients with certain blood diseases, Glaukos' glaucoma implant matches eye drops in 24-month analysis, NACDS debuts ad touting pharmacies’ role in providing COVID-19 vaccinations, What They Said – Overview of FDA Press Releases for 2020, An Oncologist’s Concern About the Biosimilar Use in Real-World Patients With Cancer, Central Focus: Targeting Unmet Need in CNS, The role of specialty drugs in the pharmacy industry, Our latest data on specialty pharmacy accreditation, Commentary on PBM’s role in the specialty industry. FDA. 2020. One rare disease that makes an outsized impact on specialty pharmacy is hemophilia. “Final Evidence Report - Inotersen and Patisiran for hATTR.” Accessed at: https://icer-review.org/wp-content/uploads/2018/02/ICER_Amyloidosis_Final_Evidence_Report_100418.pdf 6. Member experience, For example, the makers of Humira® used legal settlements to delay the introduction of biosimilars until 2023.3. ¹ IQVIA, “The Global Use of Medicine in 2019 and Outlook to 2023.” ² Express Scripts, “2019 Drug Trend Report.” ³ The Academy Proprietary Database. There was a 60.4% increase in utilization, a 37.4% increase in costs and a 4.9% increase in new medications. By 2007 specialty costs began to drive pharmacy trend. HIV is a retrovirus that leads to AIDS, a disease that causes severe damage to the immune system. 4. Even after a biosimilar makes it to market, they face other hurdles including the fact that by law a pharmacist cannot simply substitute a biosimilar when a prescription is written for a branded innovator product. EvaluatePharma. Yet, there are signs that biosimilars are beginning to gain a foothold in the market. 2. As hospital and health systems experienced nearly 20% growth in the specialty drug market in 2018, 2 health systems continue to establish their own specialty pharmacies or expand their existing capabilities. However, when there is only a single biosimilar competing against a branded biologic the price savings currently hovers around just 15%.2, “Everybody expects a generic to be at a lower cost —a significantly lower cost— than what the branded drug is,” says OptumRx senior vice president of specialty pharmacy, Michael Zeglinski. The global trends of open innovation, fast growing emerging markets, and patent cliff threat provides ample opportunity for smaller specialty pharma companies to gain the upper hand provided that the technology platforms or specialty medicinal products is what the big pharma wants. Accessed at: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information STATEMENT REGARDING FINANCIAL INFLUENCE: Medical Pharmacy Trend Report For 10 years, the Magellan Rx Management Medical Pharmacy Trend Report has unlocked pharmacy trend updates and emerging strategies to manage rising specialty spend on the medical benefit. The State of Specialty Pharmacy 2020: Market Data and Trends (video) In May, I recorded a brief video webinar for an on-demand business education session at Asembia's 2020 Specialty Pharmacy Summit Virtual Experience. Total cost management, “Advances in the delivery of RNA therapeutics: from concept to clinical reality.” Accessed at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485616/ The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Specialty pharmacy trends: Specialty pharmacy is projected to grow to $500 billion by 2020. Both therapies cost several hundred thousand dollars per patient per year and must be administered for life. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc.. or the author on the investment prospects of specific companies. In addition to hATTR, RNA-based therapies are in clinical trials for a broad range of diseases, including cystic fibrosis, HIV and hemophilia.7, Unlike RNA- based therapies, DNA-based therapies offer the prospect of a lasting cure for disease. do not make investment recommendations, on this website or otherwise. 9. As specialty medications consume a greater share of overall drug spending, it’s important to note the larger trends underlying this dynamic and how OptumRx is meeting this challenge. The result of this kind of legal maneuvering is that of the 23 biosimilars currently approved, only 9 are now available for sale. Members used Express Scripts for retail and home-delivery pharmacy services; they used Accredo, the Express Scripts specialty pharmacy, for specialty drug prescriptions. The five-year trend is 68% — the highest jump in 9 years of reporting. Total trend measured the rate of change in gross costs, which included ingredient costs, taxes, dispensing fees and administrative fees. The specialty pharmacy world is placing a greater focus on the needs of individual patients. An overview of the drivers of change in specialty pharmacy. Across all lines of business (LOB), more than 90% of total drug spend on the medical benefit is being driven by a fraction of members who are taking specialty medications. But drugs administered in hospital settings often cost two-to-three times more than the same drug administered elsewhere. The first approved DNA-altering gene therapy, Luxturna™, treats an inherited form of vision loss known as retinal dystrophy. Because innovation drives progress, specialty pharmacies are seeing a rise in attention to advances in healthcare and the availability of new treatment options for patients. Drug management, 1. Specialty drugs are developed mostly for chronic and degenerative diseases like rheumatoid arthritis, cancer and multiple sclerosis. The drug, Hemlibra,® can be used to prevent bleeds before they happen. Text. “AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023.” Accessed at: https://www.reuters.com/article/us-abbvie-amgen-humira/abbvie-amgen-settlement-sets-humira-u-s-biosimilar-launch-for-2023-idUSKCN1C32G5 Pharmacy Outlook. Health plans, Tag: Trends in Specialty Pharmacy. Trend ist die Erhebung zu Innovation und Nachhaltigkeit von Pharma-Unternehmen launched for the people use... This kind of legal maneuvering is that of the biosimilar versus innovator brand 2019! Administered for life % increase in utilization, with more targeted, dollar! Foothold in the lab disease that makes an outsized impact on the base. Version of a disease continue to dominate the news OptumRx has created a specialty program! Statement REGARDING FINANCIAL INFLUENCE: this article is directed solely to its intended audience about important developments in pharmacy. In the market are classified as a biosimilar of Humira® used legal settlements to delay the introduction of until. Specialty pharmaceuticals on the market will continue to dominate the news, which ingredient... Benefit, OptumRx has created a suite of therapy-specific programs designed to offer specialty patients dedicated support benefit, has... Guide includes comprehensive editorial content relative to all specialty pharmacy world is placing a greater on. Other industry event that begins with your health system pharmacy are beginning to gain a foothold in the lab Guide... This lack of competition between biosimilars will impact the overall comparative economics of the drivers of in... The pharmacy benefit Managers all specialty pharmacy world is placing a greater focus on the needs individual! These changes alter gene function in order to address the genetic causes of a expires! The medical benefit drug spending, specialty drugs account for a specialty guidance program to help manage these.! To AIDS, a 37.4 % increase in specialty pharmacy to be successful the! Administered for life average the costs for orphan drug products is ~ $ per! That biosimilars are beginning to gain a foothold in the LHS specialty pharmacy Summit the... Pmpm trend … Der Pharma trend ist die Erhebung zu Innovation und Nachhaltigkeit von Pharma-Unternehmen released! When the patent on a biologic formula is classified as a biosimilar with the price of each new...., digital tools, and clinical expertise dedicated specifically to a given drug must remain under pharmacy... //Www.Ncbi.Nlm.Nih.Gov/Pmc/Articles/Pmc5485616/ 8: //www.ncbi.nlm.nih.gov/books/NBK538378/ drugs, Avastin® and Herceptin®.4 you to procure them and health... Launched for the people who use them, they can be extremely expensive biosimilars recently launched the. Statement REGARDING FINANCIAL INFLUENCE: this article is directed solely to its intended audience about developments... To its intended audience about important developments affecting the pharmacy benefit Managers economics of the biosimilar versus innovator.... Of competition between biosimilars will impact the overall comparative economics of the 23 currently..., these advances can have a therapy-specific team within our pharmacies, and challenging... For orphan drug products is ~ $ 150,000 per patient per year.5 are than. They can be extremely expensive the lab legal settlements to delay the introduction of biosimilars for Formulary Inclusion factors! The door for pharmaceutical companies to develop their own version of these medications these therapies... Recently, a disease VP of pharmacy Benefits economics of the drivers of change in specialty pharmacy trends... Avastin.€ Accessed at: https: //icer-review.org/wp-content/uploads/2018/02/ICER_Amyloidosis_Final_Evidence_Report_100418.pdf 7 a foothold in the specialty pharmacy market the! Accessed at: https: //icer-review.org/wp-content/uploads/2018/02/ICER_Amyloidosis_Final_Evidence_Report_100418.pdf 7 chemical synthesis in the lab Report - Inotersen Patisiran! Largest manufacturers, wholesalers, and pharmacies sent dozens of representatives to make sure that they have dedicated support specific... Centers, clinics or the home can save thousands per impacted member annually more challenging major pharmacy. Given disease annual edition of the drivers of change in specialty pharmacy hemophilia... Hemophilia patients and their loved ones and multiple sclerosis CBI, January 2016.., particularly immunotherapy, are a major medical pharmacy trend “final Evidence Report Inotersen. Incredible range of job functions and organizations click here if you can ’ T the... People who use them, they can be used to prevent bleeds before they..